logo
logo

Newron Receives Fourth Tranche From Financing Agreement With European Investment Bank (Eib)

Newron Receives Fourth Tranche From Financing Agreement With European Investment Bank (Eib)

09/06/21, 3:54 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/IT.svgmilan
Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 4 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe. Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system

Company Info

Company
Newron Pharmaceuticals
Location
milan, lombardy, italy
Additional Info
We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system